查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1403359

骨髓增生性疾病市場至2030年的預測：按類型、診斷和篩檢方法、治療方案、最終用戶和地區的全球分析

Myeloproliferative Disorders Market Forecasts to 2030 - Global Analysis By Type, Diagnosis and Screening Methods, Treatment Option, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的資料，全球骨髓增生性疾病市場在預測期內將以 4.4%的年複合成長率成長。

稱為骨髓增殖性疾病（MPD）的罕見血液疾病群的定義是骨髓中成熟血球的過度生成。紅血球、白血球和血小板都是受這種異常生長影響的細胞。定期監測對於疾病管理和預防急性白血病的潛在進展非常重要。治療的目標是盡量減少症狀，減少併發症並阻止症狀惡化。

根據國際癌症研究機構提供的2021年資料，2020年歐洲地區癌症患者人數為479萬人，預計2040年將增加至607萬人。

對疾病意識的需求不斷成長

隨著公眾和醫療保健專業人員對這些疾病的認知不斷增強，骨髓增生性疾病（MPD）也隨之被發現。教育、醫療保健措施和宣傳宣傳活動對於傳播意識非常重要，對創新治療方法和療法的需求也相應增加。透過這種方式，提高對該疾病的認知，鼓勵早期療育並提高受影響者的護理標準，擴大市場規模，對 MPD 產生積極影響。

昂貴的治療費用

政府和保險公司可能會發現很難承擔為骨髓增生性疾病（MPD）提供廣泛且昂貴的治療的財務負擔。藥物、治療和可能的幹細胞移植的高昂成本給患者和醫療保健系統帶來了經濟負擔，這可能會影響整體健康結果。因此，治療費用的急劇上升是骨髓增生性疾病（MPD）市場的主要抑制因素。

診斷技術的進步

分子譜分析、診斷影像和基因檢測的新發展提高 MPD 診斷的準確性和有效性。診斷技術的改進也有助於及時干預，減緩疾病的進展及其影響。此外，診斷技術的持續研發表明我們致力於最佳化骨髓增生性疾病的資訊並協助醫療保健專業人員做出明智的決策，逐步支持市場的擴張。

藥物開發中的遺傳複雜性

藥物開發工作在確定適用於 MPD 遺傳頻譜的通用分子標靶方面面臨障礙。這是因為不同的亞型，例如JAK2基因、CALR基因和MPL基因的突變，需要不同的治療方法並具有不同的疾病表現型。此外，根治性治療方法的開發和對複雜分子機制的持續研究減少，這阻礙了疾病領域的擴展。

COVID-19 的影響

這場大流行擾亂了常規醫療服務，導致許多 MPD 患者的診斷和開始治療被延誤，包括真性紅血球增多症、原發性血小板增多症和骨髓纖維化等疾病，這些疾病削弱了免疫系統。並增加感染疾病的可能性。因此，由於這些綜合因素，骨髓增生性疾病市場面臨挑戰，影響患者治療和整體市場擴張。

真性紅血球增多症（PV）領域預計在預測期內將是最大的。

真性紅血球增多症（PV）領域估計佔最大佔有率。 PV 的特徵是骨髓損傷，可導致血液黏度增加、凝血和心血管問題。進行的研究的目標是創造新的治療方法改善真性紅血球增多症患者的生活、控制症狀並降低血栓症的風險。因此，骨髓增生性疾病市場的特徵是控制疾病和改善患者整體健康之間的微妙平衡，這推動了該領域的擴張。

骨髓切片檢查領域預計在預測期內年複合成長率最高

骨髓切片檢查領域預計在預測期內年複合成長率最高。骨髓切片檢查是確定細胞生成異常和評估骨髓健康狀況的重要診斷過程。它對於了解基因突變、細胞型態和骨髓增生性疾病的病程極為重要。此外，研究人員進行實驗以改進切片檢查方法並更佳利用分子見解。這提高了診斷效用，並有助於為這些疾病制定更好的治療計劃，推動該細分市場的成長。

佔有率最大的地區

由於政府和醫療機構合作提高意識，改進診斷技術並確保獲得尖端治療方法，亞太地區在預測期內佔據了最大的市場佔有率。該地區的主要企業和主要國家，包括中國、日本和印度，致力於 MPD 創新治療的研發活動激增。這促進標靶治療和幹細胞移植等先進治療方法的引進，進一步促進了該地區的成長。

年複合成長率最高的地區：

由於分子測試和基因分析等先進的診斷工具能夠實現準確的疾病識別，預計北美在預測期內將呈現最高的年複合成長率。巨量資料分析和人工智慧的這些發展支持了對 MPD 和客製化治療策略的更全面的了解。此外，Janus 激酶（JAK）抑制劑等標靶治療可提高治療效果，同時最大限度地減少副作用，因此受到關注，推動了該地區的擴張。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多3家公司）
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球骨髓增生性疾病市場：依類型

  • 真性多血症
  • 慢性骨髓性白血病（CML）
  • 原發性骨髓纖維化
  • 原發性血小板增多症
  • 其他類型

第6章 全球骨髓增生性疾病市場：依診斷及篩檢方法

  • 骨髓切片檢查
  • 驗血
  • 基因檢測

第7章 全球骨髓增生性疾病市場：依治療方案分類

  • 骨髓移植
  • 治療程序
  • 支持性護理
  • 藥品
  • 化療
  • 其他治療選擇

第8章 全球骨髓增生性疾病市場：依最終用戶分類

  • 製藥公司
  • 研究機構
  • 醫院和診所
  • 其他最終用戶

第9章 全球骨髓增生性疾病市場：依地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司簡介

  • Novartis AG
  • Teva Pharmaceutical Industries
  • AbbVie
  • Bristol Myers Squibb（BMS）
  • Roche
  • Incyte Corporation
  • Gilead Sciences
  • MP Biomedicals
  • Mylan
  • Roxall Medizin
  • AOP Orphan Pharmaceuticals AG
  • CTI BioPharma Corp
  • Promedior, Inc.
  • Celgene
Product Code: SMRC24584

According to Stratistics MRC, the Global Myeloproliferative Disorders Market is growing at a CAGR of 4.4% during the forecast period. A class of uncommon blood diseases known as myeloproliferative disorders (MPDs) is defined by the bone marrow's overproduction of mature blood cells. Red blood cells, white blood cells, and platelets are among the cells that are impacted by this aberrant proliferation. Regular monitoring is crucial for disease management and to prevent potential progression to acute leukemia. The goals of management are to minimize symptoms, cut down on complications, and stop the condition from getting worse.

According to data from 2021 provided by the International Agency for the Research on Cancer, there were 4.79 million cancer cases in the European region in 2020, and that number is projected to rise to 6.07 million by 2040.

Market Dynamics:

Driver:

Rising demand in disease awareness

Myeloproliferative Disorders (MPDs) among the general public and healthcare professionals are detected by improving recognition of these conditions. Campaigns for education, healthcare initiatives, and advocacy are essential in spreading awareness and there is a corresponding increase in demand for innovative treatments and therapies. Thus, all things considered, increased awareness of the disease has a positive impact on the MPD by encouraging early intervention and enhancing the standard of care for those who are affected which is driving the market size.

Restraint:

High cost treatment

Governments and insurance companies might find it difficult to handle the financial strain of offering extensive and expensive treatments for myeloproliferative disorder (MPD). Patients and healthcare systems bear a financial burden due to the high costs of medications, therapies, and possible stem cell transplants potentially impacting their overall health outcomes. Therefore, the high cost of treatment serves as a significant restraint in the myeloproliferative disorder (MPD) market.

Opportunity:

Technological advancements in diagnosis

New developments in molecular profiling, imaging, and genetic testing improve the precision and efficacy of MPD diagnosis. Improved diagnostic skills also make it easier to intervene quickly, which slows the course of the illness and its consequences. In addition, continuous research and development in diagnostic technologies demonstrates a dedication in optimizing the diagnosis of myeloproliferative disorders, assisting medical professionals in making well-informed decisions, and therefore gradually driving market expansion.

Threat:

Genetic complexities in drug development

Drug development efforts face obstacles in identifying common molecular targets applicable across the genetic spectrum of MPDs. This complexity makes it challenging to develop universal targeted therapies, as each subtype may require a distinct approach including mutations in JAK2, CALR, and MPL genes, leading to varied disease phenotypes. In addition, the development of curative therapies and ongoing research to intricate molecular mechanisms are decreased thereby hampering the segment expansion.

COVID-19 Impact

The pandemic has disrupted routine healthcare services, leading to delayed diagnoses and treatment initiation for many MPD patients, including conditions like polycythemia vera, essential thrombocythemia, and myelofibrosis, face heightened risks due to compromised immune systems and increased susceptibility to infections. Therefore, the market for myeloproliferative disorders faced difficulties as a result of these combined factors, which have an impact on patient care and market expansion overall.

The polycythemia vera (PV) segment is expected to be the largest during the forecast period

The Polycythemia Vera (PV) segment is estimated to hold the largest share. PV is characterized by a disorder of the bone marrow that can cause high blood viscosity, clotting, and cardiovascular problems. The goal of ongoing research is to create novel therapies that will help PV patients live better, manage their symptoms, and lower their risk of thrombosis. Thus, the myeloproliferative disorders market is characterized by a delicate balance between disease control and improving patients' overall well-being which is driving this segment expansion.

The bone marrow biopsy segment is expected to have the highest CAGR during the forecast period

The bone marrow biopsy segment is anticipated to have highest CAGR during the forecast period. It is a diagnostic process that is essential for determining abnormalities in cell production and evaluating the health of the bone marrow. They are crucial for learning about genetic mutations, cell morphology, and the course of myeloproliferative disorders. In addition, researchers are conducting experiments to improve biopsy methods and make better use of molecular insights, which will increase their diagnostic utility and help in developing better treatment plans for these conditions which are boosting this segment growth.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to governments and healthcare organizations which work together in raising awareness, advance diagnostic skills, and guarantee access to cutting-edge treatments. Key players and key countries in the region, including China, Japan, and India, have witnessed a surge in research and development activities focused on innovative therapies for MPDs. Therefore, this has resulted in introducing advanced treatment options, including targeted therapies and stem cell transplantation which further propel the growth of the region.

Region with highest CAGR:

North America is expected to witness highest CAGR over the projection period, owing to sophisticated diagnostic tools that allow for accurate disease identification, like molecular testing and genetic profiling. These developments in big data analytics and artificial intelligence support more comprehensive knowledge of MPDs and customized treatment strategies. Moreover, people are turning to targeted therapies, such as Janus kinase (JAK) inhibitors, which increase treatment efficacy while minimizing side effects, which are driving the region's expansion.

Key players in the market:

Some of the key players in the Myeloproliferative Disorders Market include Novartis AG, Teva Pharmaceutical Industries, AbbVie, Bristol Myers Squibb (BMS), Roche, Incyte Corporation, Gilead Sciences, MP Biomedicals, Mylan, Roxall Medizin, AOP Orphan Pharmaceuticals AG, CTI BioPharma Corp, Promedior, Inc. and Celgene.

Key Developments:

In October 2023, Allergan Aesthetics, an AbbVie company announced positive topline results from two pivotal Phase 3 clinical studies evaluating trenibotulinumtoxinE for the treatment of moderate to severe glabellar lines.

In September 2023, Ionis Pharmaceuticals, Inc. announced that it has entered an agreement with Roche for two undisclosed early-stage programs for RNA-targeting investigational medicines for the treatment of Alzheimer's disease (AD) and Huntington's disease (HD).

In August 2023, Halozyme Therapeutics, Inc. announced the approval of Roche's Tecentriq® SC (atezolizumab), using Halozyme's ENHANZE® drug delivery technology, by the Medicines and Healthcare Products Regulatory Agency in Great Britain.

In July 2023, DTx Pharma, a preclinical stage biotechnology company addressing the delivery challenges of oligonucleotide therapeutics with its Fatty Acid Ligand Conjugated OligoNucleotide (FALCON™) platform, announced that it has been acquired by Novartis.

Types Covered:

  • Polycythemia Vera
  • Chronic Myeloid Leukemia (CML)
  • Primary Myelofibrosis
  • Essential Thrombocythemia
  • Other Types

Diagnosis and Screening Methods Covered:

  • Bone Marrow Biopsy
  • Blood Tests
  • Genetic Testing

Treatment Options Covered:

  • Bone Marrow Transplant
  • Therapeutic Procedures
  • Supportive Care
  • Medications
  • Chemotherapy
  • Other Treatment Options

End Users Covered:

  • Pharmaceutical Companies
  • Research Institutions
  • Hospitals and Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Myeloproliferative Disorders Market, By Type

  • 5.1 Introduction
  • 5.2 Polycythemia Vera
  • 5.3 Chronic Myeloid Leukemia (CML)
  • 5.4 Primary Myelofibrosis
  • 5.5 Essential Thrombocythemia
  • 5.6 Other Types

6 Global Myeloproliferative Disorders Market, By Diagnosis and Screening Methods

  • 6.1 Introduction
  • 6.2 Bone Marrow Biopsy
  • 6.3 Blood Tests
  • 6.4 Genetic Testing

7 Global Myeloproliferative Disorders Market, By Treatment Option

  • 7.1 Introduction
  • 7.2 Bone Marrow Transplant
  • 7.3 Therapeutic Procedures
  • 7.4 Supportive Care
  • 7.5 Medications
  • 7.6 Chemotherapy
  • 7.7 Other Treatment Options

8 Global Myeloproliferative Disorders Market, By End Users

  • 8.1 Introduction
  • 8.2 Pharmaceutical Companies
  • 8.3 Research Institutions
  • 8.4 Hospitals and Clinics
  • 8.5 Other End Users

9 Global Myeloproliferative Disorders Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Novartis AG
  • 11.2 Teva Pharmaceutical Industries
  • 11.3 AbbVie
  • 11.4 Bristol Myers Squibb (BMS)
  • 11.5 Roche
  • 11.6 Incyte Corporation
  • 11.7 Gilead Sciences
  • 11.8 MP Biomedicals
  • 11.9 Mylan
  • 11.10 Roxall Medizin
  • 11.11 AOP Orphan Pharmaceuticals AG
  • 11.12 CTI BioPharma Corp
  • 11.13 Promedior, Inc.
  • 11.14 Celgene

List of Tables

  • Table 1 Global Myeloproliferative Disorders Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Myeloproliferative Disorders Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Myeloproliferative Disorders Market Outlook, By Polycythemia Vera (2021-2030) ($MN)
  • Table 4 Global Myeloproliferative Disorders Market Outlook, By Chronic Myeloid Leukemia (CML) (2021-2030) ($MN)
  • Table 5 Global Myeloproliferative Disorders Market Outlook, By Primary Myelofibrosis (2021-2030) ($MN)
  • Table 6 Global Myeloproliferative Disorders Market Outlook, By Essential Thrombocythemia (2021-2030) ($MN)
  • Table 7 Global Myeloproliferative Disorders Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 8 Global Myeloproliferative Disorders Market Outlook, By Diagnosis and Screening Methods (2021-2030) ($MN)
  • Table 9 Global Myeloproliferative Disorders Market Outlook, By Bone Marrow Biopsy (2021-2030) ($MN)
  • Table 10 Global Myeloproliferative Disorders Market Outlook, By Blood Tests (2021-2030) ($MN)
  • Table 11 Global Myeloproliferative Disorders Market Outlook, By Genetic Testing (2021-2030) ($MN)
  • Table 12 Global Myeloproliferative Disorders Market Outlook, By Treatment Option (2021-2030) ($MN)
  • Table 13 Global Myeloproliferative Disorders Market Outlook, By Bone Marrow Transplant (2021-2030) ($MN)
  • Table 14 Global Myeloproliferative Disorders Market Outlook, By Therapeutic Procedures (2021-2030) ($MN)
  • Table 15 Global Myeloproliferative Disorders Market Outlook, By Supportive Care (2021-2030) ($MN)
  • Table 16 Global Myeloproliferative Disorders Market Outlook, By Medications (2021-2030) ($MN)
  • Table 17 Global Myeloproliferative Disorders Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 18 Global Myeloproliferative Disorders Market Outlook, By Other Treatment Options (2021-2030) ($MN)
  • Table 19 Global Myeloproliferative Disorders Market Outlook, By End Users (2021-2030) ($MN)
  • Table 20 Global Myeloproliferative Disorders Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 21 Global Myeloproliferative Disorders Market Outlook, By Research Institutions (2021-2030) ($MN)
  • Table 22 Global Myeloproliferative Disorders Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
  • Table 23 Global Myeloproliferative Disorders Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 24 North America Myeloproliferative Disorders Market Outlook, By Country (2021-2030) ($MN)
  • Table 25 North America Myeloproliferative Disorders Market Outlook, By Type (2021-2030) ($MN)
  • Table 26 North America Myeloproliferative Disorders Market Outlook, By Polycythemia Vera (2021-2030) ($MN)
  • Table 27 North America Myeloproliferative Disorders Market Outlook, By Chronic Myeloid Leukemia (CML) (2021-2030) ($MN)
  • Table 28 North America Myeloproliferative Disorders Market Outlook, By Primary Myelofibrosis (2021-2030) ($MN)
  • Table 29 North America Myeloproliferative Disorders Market Outlook, By Essential Thrombocythemia (2021-2030) ($MN)
  • Table 30 North America Myeloproliferative Disorders Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 31 North America Myeloproliferative Disorders Market Outlook, By Diagnosis and Screening Methods (2021-2030) ($MN)
  • Table 32 North America Myeloproliferative Disorders Market Outlook, By Bone Marrow Biopsy (2021-2030) ($MN)
  • Table 33 North America Myeloproliferative Disorders Market Outlook, By Blood Tests (2021-2030) ($MN)
  • Table 34 North America Myeloproliferative Disorders Market Outlook, By Genetic Testing (2021-2030) ($MN)
  • Table 35 North America Myeloproliferative Disorders Market Outlook, By Treatment Option (2021-2030) ($MN)
  • Table 36 North America Myeloproliferative Disorders Market Outlook, By Bone Marrow Transplant (2021-2030) ($MN)
  • Table 37 North America Myeloproliferative Disorders Market Outlook, By Therapeutic Procedures (2021-2030) ($MN)
  • Table 38 North America Myeloproliferative Disorders Market Outlook, By Supportive Care (2021-2030) ($MN)
  • Table 39 North America Myeloproliferative Disorders Market Outlook, By Medications (2021-2030) ($MN)
  • Table 40 North America Myeloproliferative Disorders Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 41 North America Myeloproliferative Disorders Market Outlook, By Other Treatment Options (2021-2030) ($MN)
  • Table 42 North America Myeloproliferative Disorders Market Outlook, By End Users (2021-2030) ($MN)
  • Table 43 North America Myeloproliferative Disorders Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 44 North America Myeloproliferative Disorders Market Outlook, By Research Institutions (2021-2030) ($MN)
  • Table 45 North America Myeloproliferative Disorders Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
  • Table 46 North America Myeloproliferative Disorders Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 47 Europe Myeloproliferative Disorders Market Outlook, By Country (2021-2030) ($MN)
  • Table 48 Europe Myeloproliferative Disorders Market Outlook, By Type (2021-2030) ($MN)
  • Table 49 Europe Myeloproliferative Disorders Market Outlook, By Polycythemia Vera (2021-2030) ($MN)
  • Table 50 Europe Myeloproliferative Disorders Market Outlook, By Chronic Myeloid Leukemia (CML) (2021-2030) ($MN)
  • Table 51 Europe Myeloproliferative Disorders Market Outlook, By Primary Myelofibrosis (2021-2030) ($MN)
  • Table 52 Europe Myeloproliferative Disorders Market Outlook, By Essential Thrombocythemia (2021-2030) ($MN)
  • Table 53 Europe Myeloproliferative Disorders Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 54 Europe Myeloproliferative Disorders Market Outlook, By Diagnosis and Screening Methods (2021-2030) ($MN)
  • Table 55 Europe Myeloproliferative Disorders Market Outlook, By Bone Marrow Biopsy (2021-2030) ($MN)
  • Table 56 Europe Myeloproliferative Disorders Market Outlook, By Blood Tests (2021-2030) ($MN)
  • Table 57 Europe Myeloproliferative Disorders Market Outlook, By Genetic Testing (2021-2030) ($MN)
  • Table 58 Europe Myeloproliferative Disorders Market Outlook, By Treatment Option (2021-2030) ($MN)
  • Table 59 Europe Myeloproliferative Disorders Market Outlook, By Bone Marrow Transplant (2021-2030) ($MN)
  • Table 60 Europe Myeloproliferative Disorders Market Outlook, By Therapeutic Procedures (2021-2030) ($MN)
  • Table 61 Europe Myeloproliferative Disorders Market Outlook, By Supportive Care (2021-2030) ($MN)
  • Table 62 Europe Myeloproliferative Disorders Market Outlook, By Medications (2021-2030) ($MN)
  • Table 63 Europe Myeloproliferative Disorders Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 64 Europe Myeloproliferative Disorders Market Outlook, By Other Treatment Options (2021-2030) ($MN)
  • Table 65 Europe Myeloproliferative Disorders Market Outlook, By End Users (2021-2030) ($MN)
  • Table 66 Europe Myeloproliferative Disorders Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 67 Europe Myeloproliferative Disorders Market Outlook, By Research Institutions (2021-2030) ($MN)
  • Table 68 Europe Myeloproliferative Disorders Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
  • Table 69 Europe Myeloproliferative Disorders Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 70 Asia Pacific Myeloproliferative Disorders Market Outlook, By Country (2021-2030) ($MN)
  • Table 71 Asia Pacific Myeloproliferative Disorders Market Outlook, By Type (2021-2030) ($MN)
  • Table 72 Asia Pacific Myeloproliferative Disorders Market Outlook, By Polycythemia Vera (2021-2030) ($MN)
  • Table 73 Asia Pacific Myeloproliferative Disorders Market Outlook, By Chronic Myeloid Leukemia (CML) (2021-2030) ($MN)
  • Table 74 Asia Pacific Myeloproliferative Disorders Market Outlook, By Primary Myelofibrosis (2021-2030) ($MN)
  • Table 75 Asia Pacific Myeloproliferative Disorders Market Outlook, By Essential Thrombocythemia (2021-2030) ($MN)
  • Table 76 Asia Pacific Myeloproliferative Disorders Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 77 Asia Pacific Myeloproliferative Disorders Market Outlook, By Diagnosis and Screening Methods (2021-2030) ($MN)
  • Table 78 Asia Pacific Myeloproliferative Disorders Market Outlook, By Bone Marrow Biopsy (2021-2030) ($MN)
  • Table 79 Asia Pacific Myeloproliferative Disorders Market Outlook, By Blood Tests (2021-2030) ($MN)
  • Table 80 Asia Pacific Myeloproliferative Disorders Market Outlook, By Genetic Testing (2021-2030) ($MN)
  • Table 81 Asia Pacific Myeloproliferative Disorders Market Outlook, By Treatment Option (2021-2030) ($MN)
  • Table 82 Asia Pacific Myeloproliferative Disorders Market Outlook, By Bone Marrow Transplant (2021-2030) ($MN)
  • Table 83 Asia Pacific Myeloproliferative Disorders Market Outlook, By Therapeutic Procedures (2021-2030) ($MN)
  • Table 84 Asia Pacific Myeloproliferative Disorders Market Outlook, By Supportive Care (2021-2030) ($MN)
  • Table 85 Asia Pacific Myeloproliferative Disorders Market Outlook, By Medications (2021-2030) ($MN)
  • Table 86 Asia Pacific Myeloproliferative Disorders Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 87 Asia Pacific Myeloproliferative Disorders Market Outlook, By Other Treatment Options (2021-2030) ($MN)
  • Table 88 Asia Pacific Myeloproliferative Disorders Market Outlook, By End Users (2021-2030) ($MN)
  • Table 89 Asia Pacific Myeloproliferative Disorders Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 90 Asia Pacific Myeloproliferative Disorders Market Outlook, By Research Institutions (2021-2030) ($MN)
  • Table 91 Asia Pacific Myeloproliferative Disorders Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
  • Table 92 Asia Pacific Myeloproliferative Disorders Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 93 South America Myeloproliferative Disorders Market Outlook, By Country (2021-2030) ($MN)
  • Table 94 South America Myeloproliferative Disorders Market Outlook, By Type (2021-2030) ($MN)
  • Table 95 South America Myeloproliferative Disorders Market Outlook, By Polycythemia Vera (2021-2030) ($MN)
  • Table 96 South America Myeloproliferative Disorders Market Outlook, By Chronic Myeloid Leukemia (CML) (2021-2030) ($MN)
  • Table 97 South America Myeloproliferative Disorders Market Outlook, By Primary Myelofibrosis (2021-2030) ($MN)
  • Table 98 South America Myeloproliferative Disorders Market Outlook, By Essential Thrombocythemia (2021-2030) ($MN)
  • Table 99 South America Myeloproliferative Disorders Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 100 South America Myeloproliferative Disorders Market Outlook, By Diagnosis and Screening Methods (2021-2030) ($MN)
  • Table 101 South America Myeloproliferative Disorders Market Outlook, By Bone Marrow Biopsy (2021-2030) ($MN)
  • Table 102 South America Myeloproliferative Disorders Market Outlook, By Blood Tests (2021-2030) ($MN)
  • Table 103 South America Myeloproliferative Disorders Market Outlook, By Genetic Testing (2021-2030) ($MN)
  • Table 104 South America Myeloproliferative Disorders Market Outlook, By Treatment Option (2021-2030) ($MN)
  • Table 105 South America Myeloproliferative Disorders Market Outlook, By Bone Marrow Transplant (2021-2030) ($MN)
  • Table 106 South America Myeloproliferative Disorders Market Outlook, By Therapeutic Procedures (2021-2030) ($MN)
  • Table 107 South America Myeloproliferative Disorders Market Outlook, By Supportive Care (2021-2030) ($MN)
  • Table 108 South America Myeloproliferative Disorders Market Outlook, By Medications (2021-2030) ($MN)
  • Table 109 South America Myeloproliferative Disorders Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 110 South America Myeloproliferative Disorders Market Outlook, By Other Treatment Options (2021-2030) ($MN)
  • Table 111 South America Myeloproliferative Disorders Market Outlook, By End Users (2021-2030) ($MN)
  • Table 112 South America Myeloproliferative Disorders Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 113 South America Myeloproliferative Disorders Market Outlook, By Research Institutions (2021-2030) ($MN)
  • Table 114 South America Myeloproliferative Disorders Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
  • Table 115 South America Myeloproliferative Disorders Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 116 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Country (2021-2030) ($MN)
  • Table 117 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Type (2021-2030) ($MN)
  • Table 118 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Polycythemia Vera (2021-2030) ($MN)
  • Table 119 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Chronic Myeloid Leukemia (CML) (2021-2030) ($MN)
  • Table 120 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Primary Myelofibrosis (2021-2030) ($MN)
  • Table 121 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Essential Thrombocythemia (2021-2030) ($MN)
  • Table 122 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 123 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Diagnosis and Screening Methods (2021-2030) ($MN)
  • Table 124 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Bone Marrow Biopsy (2021-2030) ($MN)
  • Table 125 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Blood Tests (2021-2030) ($MN)
  • Table 126 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Genetic Testing (2021-2030) ($MN)
  • Table 127 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Treatment Option (2021-2030) ($MN)
  • Table 128 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Bone Marrow Transplant (2021-2030) ($MN)
  • Table 129 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Therapeutic Procedures (2021-2030) ($MN)
  • Table 130 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Supportive Care (2021-2030) ($MN)
  • Table 131 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Medications (2021-2030) ($MN)
  • Table 132 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 133 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Other Treatment Options (2021-2030) ($MN)
  • Table 134 Middle East & Africa Myeloproliferative Disorders Market Outlook, By End Users (2021-2030) ($MN)
  • Table 135 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 136 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Research Institutions (2021-2030) ($MN)
  • Table 137 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
  • Table 138 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Other End Users (2021-2030) ($MN)